Loon provides scientifically validated, regulatory-grade agentic AI systems tailored for Health Economics and Outcomes Research (HEOR) and Health Technology Assessment (HTA). These systems accelerate evidence generation, synthesis, and forecasting to optimize drug reimbursement and streamline market access submissions. The platform offers confidence calibration, enabling researchers to de-risk decisions across the pharmaceutical lifecycle.
Funding
Funding not disclosed
Founders
Product
Problem
The process of health technology assessment (HTA) and generating real-world evidence for drug reimbursement is often slow, expensive, and requires significant manual effort, delaying patient access to novel therapies. Traditional methods struggle to keep pace with the rapidly evolving landscape of clinical data and regulatory requirements, leading to suboptimal reimbursement strategies.
Solution
Loon provides an AI-powered platform that accelerates evidence synthesis and optimizes market access strategies for pharmaceutical companies. Their Cognitive Ensemble AI Systems™ leverage machine learning and natural language processing to automate systematic literature reviews, conduct indirect treatment comparisons, and forecast drug reimbursement outcomes with increased speed and accuracy. The platform delivers HTA-grade research, enabling users to streamline global submissions, optimize value dossiers, and simulate payer decisions to maximize reimbursement success. By providing real-time insights and continuous updates, Loon helps de-risk drug reimbursement, reduce time to market, and improve patient access to innovative treatments.
Target Audience
The primary target audience includes pharmaceutical companies, biotech firms, and HEOR/market access consultancies seeking to accelerate clinical discovery, optimize HTA submissions, and improve drug reimbursement outcomes.
Features
- AI-enhanced literature screening with 98.95% sensitivity, 95.24% specificity, and 95.5% accuracy
- AI agents for full screening process (title & abstract and full text)
- AI-assisted indirect treatment comparisons aligned with EU's Joint Clinical Assessments (JCA) requirements
- HTA/payer reimbursement simulation and forecasting
- Living Global Value Dossier that integrates multiple data streams to match specific HTA requirements of various jurisdictions
- Cognitive Ensemble AI Systems™ using proprietary, patent-pending AI and ML technologies